Prescribing oral chemotherapy
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39128.449317.BE (Published 22 February 2007) Cite this as: BMJ 2007;334:376- Sandeep D Parsad, clinical haematology and oncology pharmacist,
- Mark J Ratain, Leon O Jacobson professor of medicine
- Department of Medicine, Section of Haematology/Oncology, University of Chicago, Chicago, Illinois 60637, USA
- sandeep.parsad{at}uchospitals.edu
The use of oral anticancer agents for the treatment of common malignancies has increased over the past few years. Of about 300 new anticancer agents in development, 20-25% are oral products.1 Many novel “target agents” such as inhibitors of the epidermal growth factor receptor (for example, erlotinib) and the vascular endothelial growth factor receptors (for example, sunitinib and sorafenib) are given orally. Patients prefer oral agents because they are more convenient, allow greater autonomy, and avoid venepuncture and the associated risks of indwelling venous catheters.2
Despite the advantages of oral anticancer agents, they do pose challenges such as poor compliance, a small but definite risk of unintentional overdose, and a greater risk of drug-drug and drug-food interactions. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.